Athersys to Host Investor Day in New York City
April 15 2019 - 10:00AM
Athersys, Inc. (Nasdaq: ATHX) announced today that the company will
host an investor day on Tuesday, May 14, 2019. The event will focus
on the Company’s mission, core capabilities and technologies, as
well as progress made on developing its MultiStem® product platform
and plans for the future. The investor day will include
presentations from the Company’s management team as well as experts
in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical
Director at the Eddy Scurlock Stroke Center at Houston Methodist
Hospital will be discussing the MASTERS-2 clinical trial for
stroke. Dr. Geoff Bellingan, Medical Director at University College
London Hospitals, will be discussing the MUST-ARDS clinical trial.
Ms. Eileen Rubin, President of the ARDS Foundation and ARDS
survivor, will also share perspective on ARDS and the severe impact
it has on patients.
The meeting will commence at 8:00 am ET and
conclude at 10:30 am ET. This event is open to all current
stockholders and interested investors. Advanced registration is
required to attend, as space will be limited. Interested attendees
may email irevent@athersys.com and provide their full name
and institutional affiliation, if applicable. Registered guests
will receive a confirmation email within two business days.
About Ischemic Stroke Stroke
represents an area where the clinical need is particularly
significant, since it is a leading cause of death and serious
disability worldwide, with a substantially impaired quality of life
for many stroke victims. Currently, there are nearly 17 million
people who suffer a stroke globally and more than two million
stroke victims each year in the United States, Europe and Japan,
combined. Ischemic strokes, which represent the most common form of
stroke, are caused by a blockage of blood flow in the brain that
cuts off the supply of oxygen and nutrients and can result in
long-term or permanent disability due to neurological damage.
Unfortunately, current therapeutic options for ischemic stroke
victims are limited, since the only available treatments,
administration of the clot dissolving agent tPA, or “thrombolytic,”
or surgical intervention to remove the clot, must be conducted
within several hours of the occurrence of the stroke. As a
consequence of this limited time window, only a small percentage of
stroke victims are treated with the currently available
therapy—most simply receive supportive or “palliative” care. The
long-term costs of stroke are substantial, with many patients
requiring extended hospitalization, extended physical therapy or
rehabilitation (for those patients that are capable of entering
such programs), and many require long-term institutional or family
care.About ARDS
Acute respiratory distress syndrome (ARDS) is a
serious immunological and inflammatory condition characterized by
widespread inflammation in the lungs. ARDS can be triggered by
pneumonia, sepsis, trauma or other events and represents a major
cause of morbidity and mortality in the critical care setting. It
has significant implications, as it prolongs intensive care unit
(ICU) and hospital stays and requires convalescence in the hospital
and rehabilitation. There are limited interventions and no
effective drug treatments for ARDS, making it an area of high unmet
clinical need with high treatment costs. Given ARDS high treatment
costs, a successful cell therapy could be expected to generate
significant savings for the healthcare system by reducing days on a
ventilator and in the ICU and importantly, could reduce mortality
and improve quality of life for those suffering from the condition.
The medical need for a safe and effective treatment of ARDS is
significant due to its high mortality rate, and it affects annually
approximately 400,000 - 500,000 patients in Europe, the United
States and Japan.
MultiStem cell therapy has demonstrated the
capacity to reduce inflammation, support tissue regeneration and
promote homeostasis in acute immunological and injury settings.
Preclinical data suggests that MultiStem cells may have a
protective effect by shifting the physiological response from
pro-inflammatory to anti-inflammatory, and through the promotion of
key reparative mechanisms. In animal models, MultiStem cells have
demonstrated an ability to reduce inflammation, reduce fluid
retention in the lungs and return lung function to normal.
Intravenous MultiStem treatment early following the onset of ARDS
may ameliorate the initial inflammation and reduce the fibrotic
activity that follows, thereby speeding the return to and improving
the likelihood of more normal lung function and helping patient
recovery.
About MultiStem
MultiStem cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors
produced in response to signals of inflammation and tissue damage.
MultiStem therapy’s potential for multidimensional therapeutic
impact distinguishes it from traditional biopharmaceutical
therapies focused on a single mechanism of benefit. The therapy
represents a unique "off-the-shelf" stem cell product that can be
manufactured in a scalable manner, may be stored for years in
frozen form, and is administered without tissue matching or the
need for immune suppression. Based upon its efficacy profile, its
novel mechanisms of action, and a favorable and consistent safety
profile demonstrated in clinical studies, MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
About Athersys
Athersys is an international biotechnology
company engaged in the discovery and development of therapeutic
product candidates designed to extend and enhance the quality of
human life. The Company is developing its MultiStem cell therapy
product, a patented, adult-derived "off-the-shelf" stem cell
product, initially for disease indications in the neurological,
cardiovascular, and inflammatory and immune disease areas, and has
several ongoing clinical trials evaluating this potential
regenerative medicine product. Athersys has forged strategic
partnerships and a broad network of collaborations to further
advance the MultiStem cell therapy toward commercialization.
More information is available at www.athersys.com.
Contacts:
William (B.J.) Lehmann,
J.D.
President and Chief Operating
Officer
Tel: (216)
431-9900
bjlehmann@athersys.com
Karen Hunady Director of Corporate Communications and Investor
RelationsTel: (216) 431-9900khunady@athersys.com
David
Schull
Russo Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024